Similar to gefitinib, erlotinib specifically targets the epidermal growth factor receptor (EGFR) tyrosine kinase. It binds in a reversible fashion to the adenosine triphosphate (ATP) binding site of the receptor. Erlotinib has recently been shown to be a potent inhibitor of JAK2V617F activity. JAK2V617F is a mutant of tyrosine kinase JAK2, is found in most patients with polycythemia vera (PV) and a substantial proportion of patients with idiopathic myelofibrosis or essential thrombocythemia. The study suggests that erlotinib may be used for treatment of JAK2V617F-positive PV and other myeloproliferative disorders."""@en ; dct:identifier "drugbank:DB00530" ; dct:title "Erlotinib"@en ; adv:Drug ; rdfs:label "Erlotinib [drugbank:DB00530]"@en ; rdfs:seeAlso <http://www.drugbank.ca/drugs/DB00530> , <http://www.drugs.com/cdi/erlotinib.html> , <http://www.rxlist.com/cgi/generic4/tarceva.htm> . }